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A B S T R A C T
Background
Bronchiectasis is a chronic respiratory disease characterised by abnormal and irreversible dilatation of the smaller airways and associated
with a mortality rate greater than twice that of the general population. Antibiotics serve as front-line therapy for managing bacterial
load, but their use is weighed against the development of antibiotic resistance. Dual antibiotic therapy has the potential to suppress
infection from multiple strains of bacteria, leading to more successful treatment of exacerbations, reduced symptoms, and improved
quality of life. Further evidence is required on the efficacy of dual antibiotics in terms of management of exacerbations and extent of
antibiotic resistance.
Objectives
To evaluate the effects of dual antibiotics in the treatment of adults and children with bronchiectasis.
Search methods
We identified studies from the Cochrane Airways Group Specialised Register (CAGR), which includes the Cochrane Central Register
of Controlled Trials (CENTRAL), MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL),
Allied and Complementary Medicine (AMED), and PsycINFO, as well as studies obtained by handsearching of journals/abstracts. We
also searched the following trial registries: US National Institutes of Health Ongoing Trials Register, ClinicalTrials.gov, and the World
Health Organization (WHO) International Clinical Trials Registry Platform. We imposed no restriction on language of publication.
We conducted our search in October 2017.
Selection criteria
We searched for randomised controlled trials comparing dual antibiotics versus a single antibiotic for short-term (< 4 weeks) or long-
term management of bronchiectasis diagnosed in adults and/or children by bronchography, plain film chest radiography, or high-
resolution computed tomography. Primary outcomes included exacerbations, length of hospitalisation, and serious adverse events.
Secondary outcomes were response rates, emergence of resistance to antibiotics, systemic markers of infection, sputum volume and
purulence, measures of lung function, adverse events/effects, deaths, exercise capacity, and health-related quality of life. We did not
apply outcome measures as selection criteria.
1Dual antibiotics for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Two review authors independently screened the titles and abstracts of 287 records, along with the full text of seven reports. Two studies
met review inclusion criteria. Two review authors independently extracted outcome data and assessed risk of bias. We extracted data
from only one study and conducted GRADE assessments for the following outcomes: successful treatment of exacerbation; response
rates; and serious adverse events.
Main results
Two randomised trials assessed the effectiveness of oral plus inhaled dual therapy versus oral monotherapy in a total of 118 adults with
a mean age of 62.8 years. One multi-centre trial compared inhaled tobramycin plus oral ciprofloxacin versus ciprofloxacin alone, and
one single-centre trial compared nebulised gentamicin plus systemic antibiotics versus a systemic antibiotic alone. Published papers did
not report study funding sources.
Effect estimates from one small study with 53 adults showed no evidence of treatment benefit with oral plus inhaled dual therapy for
the following primary outcomes at the end of the study: successful management of exacerbation - cure at day 42 (odds ratio (OR)
0.66, 95% confidence interval (CI) 0.22 to 2.01; 53 participants; one study; very low-quality evidence); number of participants with
Pseudomonas aeruginosa eradication at day 21 (OR 2.33, 95% CI 0.66 to 8.24; 53 participants; one study; very low-quality evidence);
and serious adverse events (OR 0.48, 95% CI 0.08 to 2.87; 53 participants; one study; very low-quality evidence). Similarly, researchers
provided no evidence of treatment benefit for the following secondary outcomes: clinical response rates - relapse at day 42 (OR 0.57,
95% CI 0.12 to 2.69; 53 participants; one study; very low-quality evidence); microbiological response rate at day 21 - eradicated (OR
2.40, 95% CI 0.67 to 8.65; 53 participants; one study; very low-quality evidence); and adverse events - incidence of wheeze (OR
5.75, 95% CI 1.55 to 21.33). Data show no evidence of benefit in terms of sputum volume, lung function, or antibiotic resistance.
Outcomes from a second small study with 65 adults, available only as an abstract, were not included in the quantitative data synthesis.
The included studies did not report our other primary outcomes: duration; frequency; and time to next exacerbation; nor our secondary
outcomes: systemic markers of infection; exercise capacity; and quality of life. We did not identify any trials that included children.
Authors’ conclusions
A small number of studies in adults have generated high-quality evidence that is insufficient to inform robust conclusions, and studies
in children have provided no evidence. We identified only one dual-therapy combination of oral and inhaled antibiotics. Results from
this single trial of 53 adults that we were able to include in the quantitative synthesis showed no evidence of treatment benefit with
oral plus inhaled dual therapy in terms of successful treatment of exacerbations, serious adverse events, sputum volume, lung function,
and antibiotic resistance. Further high-quality research is required to determine the efficacy and safety of other combinations of dual
antibiotics for both adults and children with bronchiectasis, particularly in terms of antibiotic resistance.
P L A I N L A N G U A G E S U M M A R Y
Dual antibiotics for bronchiectasis
Background to the question
Bronchiectasis is a lung disease involving abnormal airways, leading to repeated chest infections, and associated with a mortality rate
more than twice that of the general population. Although previously considered a relatively rare disease, numbers appear to be increasing,
particularly for those over 75 years in low/middle-income countries. Antibiotics are the main therapy for chest infection, but their
use must be weighed against potential side effects and the risk of increasing resistance to antibiotic therapy. One strategy to improve
response and/or reduce antibiotic resistance involves giving two antibiotic agents at the same time: dual antibiotic therapy. This review
therefore aimed to evaluate the effects of dual antibiotics for treatment of adults and children with bronchiectasis.
Study characteristics
In October 2017, we identified two relevant studies comparing oral plus inhaled dual therapy versus oral therapy alone. They included
a total of 118 adults with an average age of 62.8 years. One study compared inhaled tobramycin plus oral ciprofloxacin with oral
ciprofloxacin, and the second study compared inhaled gentamicin plus a systemic (affecting the whole body, rather than just the lungs)
antibiotic with a systemic antibiotic alone. Only a research summary was available for the latter. Published papers did not report study
funding sources
Main results
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Results from one small trial of 53 adults show no evidence of treatment benefit with oral plus inhaled dual therapy in terms of successful
treatment of exacerbations, the occurrence of serious unwanted events, amount of phlegm, lung function, or resistance to antibiotic
treatment. However, we found insufficient evidence to permit confident conclusions about their use.
Quality of the evidence
The overall quality of the evidence was very poor, largely because one of the studies was not well described and included few participants.
Information on exacerbations, exercise ability, and quality of life was not reported. We did not identify any trials that compared other
types of dual antibiotic therapy, and we found none that included children. Therefore uncertainty remains concerning the use of dual
antibiotics, and further high-quality studies are needed to examine the role of dual antibiotics in the treatment of adults and children
with bronchiectasis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oral + inhaled dual therapy compared with oral monotherapy for bronchiectasis
Patient or population: bronchiectasis
Setting: United Kingdom and United States
Intervention: oral + inhaled dual therapy
Comparison: oral monotherapy
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with oral
monotherapy
Risk with oral + inhaled
dual therapy
Successful treatment
of exacerbat ion: num-
ber of part icipants
cured. Outcome as-
sessed on day 42
444 per 1000 346 per 1000
(150 to 617)
OR 0.66
(0.22 to 2.01)
53
(1 RCT)
⊕©©©
Very lowa,b
Successful treatment
of exacerbat ion: num-
ber of part icipants
with P aeruginosa erad-
icat ion. Outcome as-
sessed on day 21
185 per 1000 346 per 1000
(130 to 652)
OR 2.33
(0.66 to 8.24)
53
(1 RCT)
⊕©©©
Very lowa,b
Serious ad-
verse events. Outcome
assessed on day 42
148 per 1000 77 per 1000
(14 to 333)
OR 0.48
(0.08 to 2.87)
53
(1 RCT)
⊕©©©
Very lowa,b
Treatment response:
relapse (day 42). Out-
come assessed on day
42
185 per 1000 115 per 1000
(27 to 379)
OR 0.57
(0.12 to 2.69)
53
(1 RCT)
⊕©©©
Very lowa,b
4
D
u
a
l
a
n
tib
io
tic
s
fo
r
b
ro
n
c
h
ie
c
ta
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Microbiological
response: eradicated.
Outcome assessed on
day 21
200 per 1000 375 per 1000
(143 to 684)
OR 2.40
(0.67 to 8.65)
49
(1 RCT)
⊕©©©
Very lowa,b
Hospitalisat ions Not est imable (0 studies) -
Death Not est imable (0 studies) -
Quality of lif e Not est imable (0 studies) -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI)
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one point for high risk of bias f rom incomplete outcome data
bDowngraded 2 points owing to imprecision (wide conf idence intervals crossing the line of no ef fect and few events)
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B A C K G R O U N D
Description of the condition
Bronchiectasis not attributable to cystic fibrosis has been described
as non-CF bronchiectasis but, in accordance with current clinical
guidelines, we will referred to it as “bronchiectasis” throughout
this review (Polverino 2017). Bronchiectasis is a persistent respira-
tory condition associated with progressive destruction of the air-
ways due to a ’vicious cycle’ of recurrent bacterial infection, pul-
monary inflammation, and consequent structural damage (Cole
1997; Pasteur 2010). The pathological process of bronchiectasis
leads to disruption of the normal epithelial barrier, which conse-
quently allows inhaled pathogens to both colonise the airways and
cause clinical episodes of infection (Cole 1986). In severe cases,
this cycle of infectionmay lead to repeated hospitalisation, chronic
respiratory failure, and death. An understanding of the cycle is
central to the management of bronchiectasis, as strategies to arrest
both inflammatory and bacterial components are required to limit
progression of lung injury. Approximately half of presenting cases
are idiopathic, but the most common cause is a previous chest
infection, such as bacterial pneumonia or tuberculosis (Pasteur
2010). Diagnosis is based on identification of one or more abnor-
mally dilated bronchi on high-resolution computerised tomogra-
phy (HRCT) with characteristic symptoms including breathless-
ness, chronic productive cough, and recurrent lower respiratory
tract infection (Chang 2010; Pasteur 2010; Polverino 2017). Pa-
tients colonisedwithPseudomonas aeruginosa and those with a high
annual exacerbation rate showaccelerated decline in lung function,
reduced health-related quality of life (measured via St George’s
Respiratory Questionnaire (SGRQ)), increased risk of hospitali-
sation, and increased mortality risk (Evans 1996; Martinez Garcia
2007; Wilson 1997). Low forced expiratory volume in one sec-
ond (FEV1) % predicted, a higher proportion of affected lobes,
and increased breathlessness are associated with increased risks of
hospitalisation and mortality (Chalmers 2014; Martinez Garcia
2014; Seitz 2010).
Bacteria most commonly associated with infective exacerba-
tions include non-typeable Haemophilus influenzae, P aeruginosa,
Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella
catarrhalis (Foweraker 2011). The microbiological profile differs
between adults and children, and Pseudomonas is more common
among adults. Pseudomonas is resistant to many oral antibiotics
and is very difficult to eradicate, but it is prevalent in only 0 to 6%
of children. Colonising pathogens such as Pseudomonas, H influen-
zae and M catarrhalis also commonly display antimicrobial resis-
tance as the result of frequent exposure to antimicrobial agents.
The main aims of therapeutic management include preservation
of lung function; reduction in symptoms, such as cough, breath-
lessness, and expectoration; reduction in the number and duration
of exacerbations; and improvement in quality of life (Lavery 2005;
Pasteur 2010).
Global prevalence estimates are confounded by variable diagnostic
strategies (Weycker 2005), as well as by higher prevalence rates
in developing countries (Habesoglu 2011), but the global burden
of bronchiectasis is increasing, with mortality rates rising by 3%
per year in England and Wales between 2001 and 2007 (Roberts
2010), andhospitalisations increasing by 3%per year in theUnited
States over a nine-year period (Seitz 2010). Both Roberts 2010
and Seitz 2012 reported higher prevalence rates among women
and in people over 60 years of age. More recent studies suggest
that prevalence may be increasing more rapidly than was previ-
ously estimated. In Germany in 2013, prevalence was estimated at
67 cases per 100,000 general population (Ringshausen 2015). In
the UK from 2004 to 2013, incidence rates rose by approximately
63%, with an increase from21.2 to 35.2 in women, and from 18.2
to 26.9 inmen, per 100,000 person-years (Quint 2016). Similarly,
point prevalence rose from 350.5 to 566.1 in women, and from
301.2 to 485.5 in men, per 100,000 head of population, with ap-
proximately 262,900 adults in the UK living with bronchiectasis
in 2013. The disease has a significant impact on paediatric popu-
lations: Younger children and those with more frequent exacerba-
tions experience worse quality of life (Kapur 2012a). Bronchiec-
tasis is more common in some ethnic groups, for example, south-
west Alaskan children (16:1000) and Australian indigenous chil-
dren (15:1000) (Chang 2002). Furthermore, one study reported
an estimated incidence of 3.7 per 100,000 per year among chil-
dren younger than 15 years of age in New Zealand. This equates
to a prevalence of 1:3000 children overall and 1:625 in Pacific
children (Twiss 2005). It also demonstrates that the incidence rate
among children in New Zealand is almost seven times higher than
among those in Finland (Twiss 2005). Average mortality rates per
100,000 general population in Europe are estimated at 0.3 in 27
of the 28 EU countries (ranging from 0.01 in Germany to 1.18
in the UK) and at 0.2 in nine non-EU countries (ranging from
0.01 in Azerbaijan to 0.67 in Kyrgyzstan), on the basis of 2005 to
2009 data (European Lung White Book 2013). More recent UK
estimates suggest that age-adjusted mortality rates are 2.26 times
higher in women and 2.14 times higher in men compared with
the general population (Quint 2016).
Description of the intervention
The lungs of patients with bronchiectasis are commonly colonised
by bacteria, and treatment with antibiotics can help to de-
crease bacterial load while reducing systemic inflammation (Kapur
2012). Antibiotics are used to reduce bacterial burden and to tackle
the cycle of infection and lung damage, consequently helping to
reduce the impact and frequency of chest infection and the fre-
quency and duration of hospital admissions, while also reducing
mortality (Cole 1986; Pasteur 2010). Antibiotics can be adminis-
tered on a short-term (< 4 weeks) or longer-term (≥ 4 weeks) basis
via various modes, including oral, inhaled, and intravenous routes,
with specific choice of antibiotic informed by analysis of sputum
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bacteriology. Antibiotics serve as front-line therapy for manage-
ment of bacterial load, but their use is weighed against potential
adverse effects and increasing concerns about antibiotic resistance
(Pasteur 2010).
’Combination’ or ’dual’ antibiotic therapy for bronchiectasis is de-
fined as the combination of two or more antibiotics, rather than as
use of a single antibiotic (monotherapy), irrespective of the route of
administration or the duration of therapy. Dual antibiotic therapy
is commonly administered therapeutically over a short duration
(up to fourweeks), rather thanprophylactically for prevention, and
is commonly used to treat patients with acute exacerbations whose
lungs are colonised by multiple strains of bacteria with different
patterns of antibiotic resistance, when monotherapy is unlikely to
be effective. Dual therapy may also be used when the clinician
is concerned about increasing the risk of antibiotic resistance, for
example, when antibiotics have been prescribed frequently or for
a prolonged duration. British Thoracic Society guidelines recom-
mend the use of combination antibiotics when patients present
with multiple pathogens (Pasteur 2010).
How the intervention might work
Chronic bacterial airway colonisation commonly occurs in pa-
tients with bronchiectasis; high bacterial load is associated with
increased inflammation and symptoms and worse quality of life
(McShane 2013). It has been hypothesised that inflammation con-
tributes to progression of bronchiectasis, and evidence suggests
that the presence of bacteria in the airways promotes inflammation
(Haworth 2014). Bronchiectatic airways are commonly colonised
by multiple bacteria or different strains of the same bacteria, some
of which may not be positively cultured in the laboratory. Bac-
terial load can be reduced through treatment with systemic an-
tibiotics (Rubin 2014), and various antibiotic strategies have been
used to reduce bacterial load and reinfection, including short-term
(< 4 weeks) therapy for acute exacerbations and longer-term (≥
4 weeks) prophylactic therapy for frequent exacerbations char-
acterised by chronic sputum purulence (Chalmers 2012; Evans
2003). Although longer-term antibiotics are not recommended for
routine treatment (Valery 2012; Wu 2014), they may be consid-
ered for treatment of patients with frequent exacerbations (three
or more per year requiring antibiotic therapy) (Pasteur 2010).
Dual antibiotic therapy for exacerbations could reduce bacterial
load and levels of inflammation, consequently improving clinically
meaningful outcomes, such as length of exacerbation, frequency
of exacerbation, disease progression, and mortality.
Why it is important to do this review
The benefits and risks of dual antibiotics given for management
of acute exacerbations and for prophylaxis are currently unclear. It
is important to weigh the benefits of dual antibiotics in terms of
bacterial eradication and suppression of bacterial load against the
risks of enhanced antibiotic resistance and exposure to side effects
associated with multiple antibiotic therapy.
This review summarises available evidence on the use of dual an-
tibiotics for patients with bronchiectasis to inform clinical prac-
tice and future research needs. This review has been conducted
alongside two other, closely related reviews: Macrolide antibiotics
for bronchiectasis (Kelly 2018) andHead-to-head trials of antibiotics
for bronchiectasis (Kaehne 2017).
O B J E C T I V E S
To evaluate the effects of dual antibiotics in the treatment of adults
and children with bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) reported as full
text, those published as abstract only, and unpublished data.
Types of participants
We included adults and children with a clinical diagnosis of
bronchiectasis confirmed by plain film chest radiography or
HRCT. We excluded studies in which participants had received
continuous or high-dose antibiotics immediately before the study
began or a diagnosis of cystic fibrosis (CF), sarcoidosis, or active
allergic bronchopulmonary aspergillosis.
Types of interventions
We included studies comparing dual antibiotics versus a single
antibiotic, provided that both arms included a common route of
administration. We planned to analyse short-course (< 4 weeks)
and long-term (≥ 4 weeks) dual antibiotics separately. This review
focused on comparisons of antimicrobial agents and therefore ex-
cluded comparisons of macrolides owing to their anti-inflamma-
tory properties. Potential comparison groups for dual therapy ver-
sus monotherapy included the following.
1. Oral dual therapy versus oral monotherapy.
2. Intravenous dual therapy versus intravenous monotherapy.
3. Oral + inhaled dual therapy versus oral monotherapy.
4. Oral + intravenous dual therapy versus oral monotherapy.
5. Inhaled + intravenous dual therapy versus inhaled
monotherapy.
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6. Inhaled + oral dual therapy versus inhaled monotherapy.
7. Intravenous + inhaled dual therapy versus intravenous
monotherapy.
8. Intravenous + oral dual therapy versus inhaled
monotherapy.
We included studies that compared one combination of antibiotics
versus another if a comparison was made between different classes
of antibiotics in combination (e.g. cephalosporin A + aminoglyco-
side A vs cephalosporin B + inhaled aminoglycoside B) or between
different administration routes for antibiotics from the same class
(e.g. IV cephalosporin + IV aminoglycoside vs IV cephalosporin
+ inhaled aminoglycoside).
Types of outcome measures
Primary outcomes
1. Successful treatment of exacerbation
2. Length of exacerbation
3. Length of hospitalisation
4. Time to next exacerbation
5. Frequency of exacerbations
6. Serious adverse event - We used the definitions from
Hansen 2015 to describe serious adverse events, which were
those that resulted in death or life-threatening events;
requirement for hospitalisation or prolongation of existing
hospitalisation; persistent or significant disability; or congenital
anomalies, or events that were considered medically important.
Secondary outcomes
1. Response rates as defined by study authors (e.g. diary cards
of physician global assessment)
2. Sputum volume and purulence
3. Measures of lung function (e.g. forced expiratory volume in
one second (FEV1))
4. Systemic markers of infection (e.g. leucocyte count, C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR))
5. Adverse events (e.g. cardiac arrhythmias, GI symptoms,
hearing impairment, nephrotoxicity)
6. Deaths
7. Emergence of resistance to antibiotics
8. Exercise capacity (e.g. Six-Minute Walk Distance
(6MWD))
9. Quality of life (e.g. St George’s Respiratory Questionnaire
(SGRQ))
10. Adverse/side effects
Reporting one ormore of these outcomeswas not a study inclusion
criterion for this review.
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org).
2. Weekly searches of MEDLINE Ovid SP 1946 to date.
3. Weekly searches of Embase Ovid SP 1974 to date.
4. Monthly searches of PsycINFO Ovid SP 1967 to date.
5. Monthly searches of Cumulative Index to Nursing and
Allied Health Literature (CINAHL) EBSCO 1937 to date.
6. Monthly searches of Allied and Complementary Medicine
(AMED) EBSCO.
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings, are provided in Appendix 1. See Appendix 2 for search
terms used to identify studies for inclusion in this review.
We will search the following trials registries.
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov).
2. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch).
We searched the Cochrane Airways Trials Register and additional
sources from inception to October 2017, with no restriction on
language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We also searched for errata or
retractions from included studies published in full text on PubMed
(www.ncbi.nlm.nih.gov/pubmed) and reported the search date.
Data collection and analysis
Selection of studies
Two review authors (LF and SG) independently screened titles
and abstracts of all studies identified for inclusion as a result of the
search and coded them as ’retrieve’ (eligible or potentially eligible/
unclear) or ’do not retrieve.’ The same two review authors indepen-
dently screened retrieved full-text study reports or publications for
inclusion and recorded reasons for exclusion of ineligible studies.
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They reported no disagreements with regard to study selection.We
recorded the study selection process using a PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) flow
diagram and study details using Characteristics of excluded studies
tables (Moher 2009).
Data extraction and management
We used a data collection form, piloted on at least one study in
the review, to record study characteristics and outcome data. One
review author (RA) extracted the following study characteristics
from included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals, dates of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (DL and LF) independently extracted out-
come data from included studies and noted in the Characteristics
of included studies table when outcome data were not reported in
a useable way. We resolved disagreements by consensus or by con-
sultation with a third review author (SS or SJM). One review au-
thor (DL) transferred data into Review Manager (RevMan 2014).
We double-checked that data had been entered correctly by com-
paring data presented in the systematic review with those provided
in the study reports. A second review author (RA) spot-checked
study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (DL and LF) independently assessed the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements by discussion with another review au-
thor (SS). We assessed risk of bias according to the following do-
mains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
risk of bias judgements across different studies for each of the
domains listed.We considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different from risk
of bias for a patient-reported pain scale). When information on
risk of bias was related to unpublished data or correspondence
with a trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account risk of
bias for studies that contributed to those outcomes.
Assessment of bias in conducting the systematic review
We conducted the review according to the published protocol
(Felix 2017).
Measures of treatment effect
We analysed dichotomous data as odds ratios, and continuous data
as mean differences or standardised mean differences. We entered
data presented as a scale with a consistent direction of effect.
We intended toundertakemeta-analyses onlywhen thiswasmean-
ingful (i.e. when treatments, participants, and the underlying clin-
ical question were similar enough for pooling to make sense).
However, data were available from only one included study, and
meta-analysis was not possible. Nevertheless, we included the data
narratively in the review.
We planned to narratively describe skewed data reported as medi-
ans and interquartile ranges.
If multiple arms had been reported in a single trial, we planned to
include only the relevant arms. Similarly, if two comparisons (e.g.
drug A vs placebo and drug B vs placebo) had been combined in
the same meta-analysis, we would have halved the control group
to avoid double-counting. None of the included studies included
more than two study arms.
Unit of analysis issues
In all included studies, the unit of analysis was the participant. In
terms of exacerbation rates and hospitalisation rates, we focused
on the number of events experienced by the participant during the
trial and analysed the results using rate ratios when possible.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data (e.g.
when a study was identified as abstract only). When this was not
possible, and the missing data were considered a serious source of
bias, we had planned to perform a sensitivity analysis to explore
the impact of including such studies in the overall assessment of
results.
One of the included studies was an abstract for which contact de-
tails for the principal investigator were not reported.We contacted
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the institution to which the authors were affiliated to obtain more
information.
Assessment of heterogeneity
We planned to use the I² statistic to measure heterogeneity among
studies in meta-analyses; in the presence of substantial heterogene-
ity, we would have explored possible causes by performing pre-
specified subgroup analyses. As we conducted no meta-analyses,
we did not assess heterogeneity.
Assessment of reporting biases
Only two studies met the inclusion criteria; thus we identified
fewer than the recommended minimum number of eight studies
required to create a funnel plot to explore possible small-study and
publication biases.
We were not able to pool the included studies and therefore were
unable to explore small-study and publication biases.
Data synthesis
We planned to use a random-effects model for meta-analyses and
to perform a sensitivity analysis using a fixed-effect model, but this
was not possible, as we were unable to pool data from the included
studies.
’Summary of findings’ table
We created a ’Summary of findings’ table using the following pri-
mary and secondary outcomes: exacerbations, hospitalisations, se-
rious adverse events, response rates, deaths, and quality of life. We
used the five GRADE considerations (study limitations, consis-
tency of effect, imprecision, indirectness, and publication bias) to
assess the quality of evidence related to included studies that con-
tributed data on our prespecified outcomes. We followedmethods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), and we used GRADEpro software (GRADEpro
GDT). We justified all decisions to downgrade or upgrade the
quality of studies by using footnotes and inserted comments to
aid the reader’s understanding of grades when necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Duration: short (< 4 weeks) or longer (≥ 4 weeks).
2. Type of antibiotic: aminoglycosides, beta-lactams,
chloramphenicol, fluoroquinolones, macrolides, tetracyclines.
3. Children versus adults.
4. Pseudomonas colonisation versus no Pseudomonas
colonisation.
We planned to use the following outcomes.
1. Exacerbations.
2. Hospitalisations.
3. Serious adverse events.
We planned to use the formal test for subgroup interactions pro-
vided in Review Manager (RevMan 2014).
However data available from the two included studies were insuf-
ficient to permit subgroup analyses.
Sensitivity analysis
We planned to evaluate the impact of methodological quality of
included studies using the following domains to remove studies
at high or unclear risk of bias: random sequence generation and
allocation concealment. Data were insufficient to undertake sen-
sitivity analyses.
R E S U L T S
Description of studies
Results of the search
A systematic search, conducted in October 2017, identified 287
unique records of potentially relevant trials. Following inspection
of titles and abstracts, review authors considered 280 records as
irrelevant. We obtained full texts for the remaining seven records
and included two studies that met review eligibility criteria (Bilton
2006; Hossain 2010). See Characteristics of included studies.
We excluded five records with reasons (documented in Excluded
studies) and summarised the selection process in the study flow
diagram (Figure 1).
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Figure 1. Study selection flow diagram.
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One included study originally aimed to test the use of nebu-
lised tobramycin tomanage exacerbations of bronchiectasis (Bilton
2006).However, in keepingwith recommendations of the research
ethics committee (communication with authors), investigators re-
designed the trial to test the effectiveness of tobramycin inhalation
plus oral ciprofloxacin compared with placebo inhalation plus oral
ciprofloxacin. We included the redesigned published study in this
review.
Included studies
Methods
Both of the included studies were RCTs (Bilton 2006; Hossain
2010). Bilton 2006 was conducted in multiple centres across UK
and USA, and Hossain 2010 was conducted at a single centre in
Bangladesh.
Ten participants withdrew from Bilton 2006 (five in the oral +
inhaled dual therapy (O + I) group, five in the oral monotherapy
(O) group).
Participants
The two studies included a total of 118 participants (Bilton 2006
= 53; Hossain 2010 = 65). Adults (72% female) aged 18 to 80
years with a mean age of 62.8 years (± 11.5 years) participated
in Bilton 2006. Bronchiectasis was confirmed by HRCT scan,
and researchers excluded from the study those with CF, aller-
gic bronchopulmonary aspergillosis, active tuberculosis, glucose-
6-phosphate dehydrogenase deficiency, significant renal disease,
or change in steroid therapy within 2 weeks of the acute exacerba-
tion. In addition, eligibility criteria included a history of chronic
P aeruginosa, confirmed by sputum culture, during the previous
12 months and at screening. Furthermore, the P aeruginosa iso-
late had to demonstrate sensitivity to ciprofloxacin (minimum in-
hibitory concentration ≤ 4 µg/mL) at study enrolment. The sec-
ond study was reported as an abstract alone and did not provide
detailed information on participant characteristics or study inclu-
sion/exclusion criteria (Hossain 2010).
Smoking history
In Bilton 2006, one participant was a current smoker (placebo/
oral ciprofloxacin group) and 20 participants (13 placebo/oral ci-
profloxacin; 7 tobramycin/oral ciprofloxacin) were former smok-
ers. Hossain 2010 did not report smoking history.
Interventions
Both studies assessed the effectiveness of oral plus inhaled dual
therapy versus oral monotherapy.
Bilton 2006 randomised participants to receive either tobramycin
inhalation solution (300 mg per 5 mL of inhalation solution)
plus oral ciprofloxacin (750 mg), or placebo (1.25 mg of quinine
sulphate per 5 mL of inhalation solution) plus oral ciprofloxacin
(750 mg), twice daily for 14 days.
Hossain 2010 randomised participants to receive either nebulised
gentamicin plus a systemic antibiotic or nebulised placebo plus a
systemic antibiotic. Study authors did not report information on
frequency and dose.
Outcomes
Primary outcomes
Successful treatment of exacerbation
Bilton 2006 reported this outcome as a cure rate using the fol-
lowing definition:resolution or improvement of symptoms of acute
exacerbation (day 21 - primary outcome).
Hossain 2010 reported this outcome using the following categori-
sation: resolved - resolution of symptoms and signs (S/S) of acute ex-
acerbation; improved - not fully resolved; not improved - no change
or deterioration of S/S.
Length of hospitalisation
Only Hossain 2010 reported this outcome.
Serious adverse events
Only Bilton 2006 reported this outcome. This study reported
the proportions of participants who required hospitalisation and
treatment for worsening symptoms such as dyspnoea, cough, chest
pain, or tightness that was associated with bronchiectasis and
chronic infection.
Length of exacerbation, time to next exacerbation, frequency
of exacerbations
The included studies did not report any of the above remaining
primary outcomes.
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Secondary outcomes
Response rates as defined by study authors (e.g. diary cards of
physician global assessment)
Bilton 2006 classified response as follows at day 21: failed - par-
ticipants with persistent or worsening symptoms of exacerbations,
hospitalisation, or administration of additional antibiotic; or in-
determinate - participants with missing data and those without a
definitive cure or failure rate; or relapse (classified on day 42) -
including those who were cured on day 21 but required further
treatment with additional antibiotics.
Bilton 2006 also classified response rates according to microbio-
logical results at day 21. Researchers classified sputum culture as
“eradicated” (no P aeruginosa infection and/or inability to produce
sputum), “persistent” (with P aeruginosa infection and/or treat-
ment with additional antibiotics for continued infection), “super-
infected” (new pathogen and new or worsening symptoms of in-
fection), or “indeterminate” (unable to classify).
Sputum volume and purulence
Only Bilton 2006 reported sputum volume. Neither of the in-
cluded studies reported sputum purulence.
Measures of lung function (e.g. forced expiratory volume in
one second (FEV1))
Bilton 2006 measured FEV1 (L) at baseline and at 7 and 14 days.
Hossain 2010 also measured FEV1 (values not given) but did not
report the details.
Serious adverse events (e.g. cardiac arrhythmias, GI
symptoms, hearing impairment, nephrotoxicity)
Both of the included studies reported serious adverse events (Bilton
2006; Hossain 2010).
Deaths
Bilton 2006 and Hossain 2010 did not report this outcome mea-
sure, and it remains unclear whether any deaths occurred during
the study period. In Bilton 2006, 7 of 10 withdrawals were due to
adverse events, but study authors did not provide follow-up data,
so we do not know whether any deaths occurred in this group.
Emergence of resistance to antibiotics
Bilton 2006 reported emergence of P aeruginosa resistance to ci-
profloxacin and tobramycin.
Adverse/side effects
Bilton 2006 reported adverse effects of study medications.
Systemic markers of infection, exercise capacity, quality of life
Included studies did not report any of the above outcomes.
Notes
Neither of the included studies reported information on power
calculation to inform sample size, trial registration, funders, or the
role of sponsors. Trial authors did not provide conflict of interest
statements. Bilton 2006 reported that researchers obtained ethical
approval for their trial.
Excluded studies
We recorded reasons for exclusion of five studies following exami-
nation of full text reports (see Characteristics of excluded studies).
Two studies did not meet study inclusion criteria for the interven-
tion, as the comparison arm was not given monotherapy (Orriols
1999; Orriols 2015). We excluded the remaining three studies be-
cause participants were not exclusively patients with bronchiecta-
sis and we were unable to contact trial authors to obtain informa-
tion on these participants alone (Takamoto 1994; Vergnon 1985;
Watanabe 1990).
Risk of bias in included studies
Two independent review authors (DL and LF) agreed on judge-
ments reported under the ’Risk of bias’ section at the end of each
Characteristics of included studies table. Figure 2 and Figure 3 also
provide a summary of the risk of bias in both included studies.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
We judged Bilton 2006 as having low risk of bias, as the randomi-
sation sequence was computer generated. However, we judged
Hossain 2010 as having unclear risk because insufficient informa-
tion was provided in the abstract.
We judged Bilton 2006 as having low risk of bias for allocation
concealment following confirmation from trial authors that as-
signment was concealed via an independent central allocation pro-
cess. We judged Hossain 2010 as having unclear risk owing to
insufficient information provided in the abstract.
Blinding
We judged Bilton 2006 as having low risk of bias for this domain.
The principal investigator confirmed that drugs were supplied by
a pharmaceutical company in identical opaque vials, and that both
drugs had a similar taste. We judged Hossain 2010 as having un-
clear risk owing to insufficient information provided in the ab-
stract.
We judged Bilton 2006 as having low risk of bias following con-
firmation from the principal investigator that outcome assessors
were blinded to group allocation.We judged Hossain 2010 as hav-
ing unclear risk owing to insufficient information provided in the
15Dual antibiotics for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
abstract.
Incomplete outcome data
We judged Bilton 2006 as having high risk of attrition bias be-
cause reasons for missing outcome data were not balanced between
intervention groups. We judged Hossain 2010 as having unclear
risk owing to insufficient information provided in the abstract.
Selective reporting
We classified risk of selective reporting bias as unclear for both of
the included studies because information on which to base a clear
judgement was insufficient (Bilton 2006; Hossain 2010).
Other potential sources of bias
We judged Bilton 2006 as having low risk of bias for this domain,
as no other sources of bias were identified. We judged Hossain
2010 as having unclear risk because information provided in the
abstract was insufficient.
Effects of interventions
See: Summary of findings for the main comparison Oral
+ inhaled dual therapy compared with oral monotherapy for
bronchiectasis
Primary outcomes
Successful treatment of exacerbation
Bilton 2006 reported no differences between groups in the number
of participants cured at day 21 (OR 0.42, 95% CI 0.14 to 1.30;
one study; 53 adults; Analysis 1.1) or at day 42 (OR 0.66, 95%CI
0.22 to 2.01; one study; 53 adults; Analysis 1.2). Researchers noted
no differences between groups in terms of number of participants
with P aeruginosa eradication at day 21 (OR 2.33, 95% CI 0.66
to 8.24; Analysis 1.3). In Hossain 2010, participants receiving
dual therapy had an enhanced recovery rate compared with those
receiving systemic antibiotics alone at three time points (P = 0.05;
P = 0.02; P = 0.02), but which of the four follow-up time points
(day 3, 7, 14, or 21) is referred to remains unclear. The study
report was available only as an abstract and did not provide any
quantitative data other than the P value.
According to our GRADE assessment, we judged this outcome as
very low quality (Summary of findings for the main comparison).
Length of hospitalisation
Hossain 2010 reported that dual therapy reduced hospital stay
among participants in the intervention group; however, the ab-
stract did not include any quantitative data.
Serious adverse events
Bilton 2006 reported no differences between groups in frequency
of serious adverse events (OR 0.48, 95% CI 0.08 to 2.87;
one study; 53 adults; Analysis 1.4). Four participants receiving
monotherapy and two receiving dual therapy required hospitalisa-
tion for worsening symptoms such as dyspnoea, cough, and chest
pain or tightness.
According to our GRADE assessment, we judged this outcome as
very low quality (Summary of findings for the main comparison).
Length of exacerbation, time to next exacerbation,
frequency of exacerbations
None of the included studies reported any of the above outcomes.
Secondary outcomes
Response rates
Response to treatment - failure or relapse
Treatment responses were not different between groups at day 21
for the classification of treatment failure (OR 2.75, 95% CI 0.79
to 9.62; one study; 53 adults; Analysis 1.5); nor at day 42 for
the classifications of treatment relapse (OR 0.57, 95% CI 0.12
to 2.69; one study; 53 adults; Analysis 1.6) and treatment failure
(OR 2.75, 95% CI 0.79 to 9.62; one study; 53 adults; Analysis
1.7). Relapse rates were not measured at day 21.
Microbiological response - eradicated, persistent,
superinfected
Microbiological response was not different between groups at day
21 for the following classifications: eradicated (OR 2.40, 95% CI
0.67 to 8.65; Analysis 1.8); persistent (OR 0.37, 95% CI 0.11 to
1.26; Analysis 1.9); and superinfected (OR 3.26, 95% CI 0.13 to
83.90; Analysis 1.10).
According to our GRADE assessment, we judged this outcome as
very low quality (Summary of findings for the main comparison).
Sputum volume and purulence
Bilton 2006 reportedno statistically significant differences inmean
sputum volume at days 7 and 14 with dual therapy compared with
monotherapy.
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Measures of lung function
Researchers noted no statistically significant differences in FEV1
between groups in the included studies. Bilton 2006 reported
mean FEV1 (L) graphically for all data collection points (days 7
and 14), but it was not possible for review authors to accurately
retrieve the raw data. Hossain 2010 did not report further details.
Systemic markers of infection
None of the included studies reported this outcome.
Adverse events
Researchers noted no differences between groups in the number
of people who experienced an adverse event in Bilton 2006 (OR
0.21, 95%CI 0.02 to 2.03; Analysis 1.11).However, the incidence
of wheeze was significantly higher in the dual therapy group com-
pared with the monotherapy group (OR 5.75, 95% CI 1.55 to
21.33; Analysis 1.12). Data show no differences between groups in
terms of adverse events arising from the use of study medications,
although it is unclear from the paper whether this relates specif-
ically to the antibiotic interventions (OR 1.45, 95% CI 0.49 to
4.31; Analysis 1.13). Hossain 2010 reported that five participants
in the dual therapy group developed wheeze and chest tightness
following administration of nebulised gentamicin. It remains un-
clear whether any of the participants in the monotherapy group
experienced an adverse event.
Deaths
Neither of the included studies explicitly reported any deaths,
Emergence of resistance to antibiotics
Data show no differences between groups in the development
of antibiotic resistance in Bilton 2006. One patient receiving
dual tobramycin+ciprofloxacin therapy entered the study with to-
bramycin-susceptible P aeruginosa strains that became resistant
by the end of the study. No participants receiving ciprofloxacin
monotherapy developed tobramycin-resistantP aeruginosa strains
during the study.
Exercise capacity
Neither Bilton 2006 nor Hossain 2010 reported this outcome.
Quality of life
Neither of the two included studies reported this outcome.
D I S C U S S I O N
Summary of main results
Two randomised trials met the inclusion criteria for this systematic
review (Bilton 2006;Hossain 2010); both assessed the effectiveness
of oral plus inhaled dual therapy versus oral monotherapy, and
bothwere conducted in adults. Bilton 2006was amulti-centre trial
conducted in UK and USA, and Hossain 2010 was a single-centre
study conducted in Bangladesh. Only an abstract was available for
Hossain 2010, and outcomes were described narratively or results
were reported as the P value alone; therefore we were unable to
include these data in the quantitative data synthesis.
We found no evidence of treatment effect with oral plus inhaled
dual therapy for all outcomes reported in the summary of findings,
including successful treatment of exacerbations, serious adverse
events, and response rates, although the effect estimate was based
on one small study of 53 adults (Bilton 2006). Similarly, we found
no evidence of effect on sputum volume, lung function, adverse
events, or antibiotic resistance.
Overall completeness and applicability of
evidence
Of the pre-defined potential comparison groups, we identified
only one group (oral plus inhaled dual therapy vs oral monother-
apy) for inclusion in the review. The comparison included only
two small studies with a total of 118 participants. Our search did
not identify any other comparisons that met our study selection
criteria. The two included studies did not report some of our pri-
mary outcomes (length, frequency, and time to next exacerbation)
and did not report some of our secondary outcomes (systemic
markers of infection, exercise capacity, and quality of life). It is
particularly important to measure the impact of this chronic con-
dition on health-related quality of life from the patient’s perspec-
tive. Furthermore, we were unable to obtain quantitative data for
pooled analyses or to adequately assess risk of bias for one study, as
findings were available only in a conference abstract. We did not
identify any studies that evaluated the use of dual antibiotics in
children, or that assessed long-term (more than four weeks) use of
dual antibiotic therapy; we identified insufficient studies to per-
mit assessment of effects by class of antibiotic. Similarly, we found
insufficient studies to conduct sensitivity analyses. Our findings
therefore are limited by scant available data, and we were unable
to evaluate all outcomes planned in the protocol.
Quality of the evidence
We judged overall quality of the evidence as very low for outcomes
included in the GRADE assessment. Only one comparison - oral
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plus inhaled dual antibiotic versus oral antibiotic alone - was as-
sessed, and included studies did not report several of the outcomes
that we planned to include in our GRADE assessment. We judged
the quality of evidence as very low for the three outcomes included
in the GRADE assessment (treatment of exacerbations, response
rate, and serious adverse events). All outcomes were limited by in-
complete outcome data. We considered effects as imprecise owing
to wide confidence intervals that crossed the line of no effect and
inclusion of few events and small sample sizes.
Potential biases in the review process
Weused a comprehensive systematic search, conducted by a highly
experienced information specialist, to identify potentially eligible
studies. We also searched multiple resources including electronic
databases, journals, conference proceedings, reference lists of in-
cluded studies, citations of included studies, and trial registries.
Nevertheless, we recognise the possibility of publication bias in
this review, which could lead to overestimation or underestimation
of effects of the intervention in terms of the different outcomes
included in this review. Trials showing no, or negative, effects are
less likely to be offered for publication, and, if offered, they are less
likely to be accepted, resulting in a biased set of data available for
review. We were able to extract quantitative data from only one
study and were unable to assess the presence of publication bias
through formal testing.
Furthermore, some papers may have been misclassified as not eli-
gible for inclusion in the review. However, two review authors in-
dependently assessed all studies, and a third review author verified
selection, so we are confident that we assessed studies excluded
from the analyses on the basis of consistent and appropriate crite-
ria. We double-checked all data to avoid extraction and transcrip-
tion errors.
We contacted the investigators of both included studies to request
further information on trial methods and outcome data. The au-
thor of one trial, published as a full-text paper, provided clarifica-
tion on randomisation procedures. We did not receive a response
from the authors of the study that was published only as an ab-
stract. We also contacted the author of one excluded study pub-
lished in a non-English language but did not receive a response.
We obtained translations of two non-English language studies that
we excluded following inspection of the translated text. We were
unable to conduct planned subgroup or sensitivity analyses owing
to the small number of included studies.
Agreements and disagreements with other
studies or reviews
There are no previous versions of this review. We included in this
review two small trials that assessed the effectiveness of oral plus
inhaled dual therapy versus oral monotherapy alone, with a to-
tal of 118 adult participants and no children. We highlighted the
paucity of evidence in this area in relation to all important out-
comes and, in accordance with this lack of evidence, identified no
published reviews of the relevant benefits and risks of combined
antibiotics compared with monotherapy in bronchiectasis. A re-
view of single versus combination intravenous antibiotics for erad-
icating Pseudomonas aeruginosa in people with cystic fibrosis found
no significant benefit associated with a beta-lactam or aminoglyco-
side monotherapy compared with a beta-lactam-aminoglycoside
combination upon examination of poor quality evidence (Elphick
2005). However, recent bronchiectasis guidelines emphasise dif-
ferences in treatment responses between bronchiectasis and cystic
fibrosis, and although the guidelines provide no specific recom-
mendations for dual therapy, they do offer recommendations for
use of antibiotics in people with this condition (Polverino 2017).
This review cannot inform robust recommendations for practice
owing to insufficient high-quality evidence, and review authors
found no evidence related to the role of dual antibiotics in the
treatment of children.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This systematic review identified minimal published evidence to
guide clinical practice on the routine use of dual antibiotics for
treatment of patients with bronchiectasis.
Only two published trials with 118 adult participants met our in-
clusion criteria; these studies evaluated the addition of nebulised
aminoglycosides to systemic antibiotics. Bilton and colleagues in-
vestigated the addition of nebulised tobramycin to oral ciproflo-
xacin for treatment of 53 adult patients with acute Pseudomonas
aeruginosa infection in bronchiectasis. Researchers found no ev-
idence of treatment benefit with oral plus inhaled dual therapy
in terms of successful treatment of exacerbations, serious adverse
events, sputum volume, lung function, and antibiotic resistance.
Hossain reported the results of a single-centre placebo-controlled
comparison of systemic antimicrobials versus the addition of neb-
ulised gentamicin, but we were unable to include this study in the
quantitative synthesis. Both studies reported a higher incidence of
wheeze with dual therapy. Overall, we have very low confidence
in the outcomes presented.
Review authors have identified the need for better quality evidence
on the benefits and risks of dual antibiotics to guide clinical prac-
tice in the treatment of patients with bronchiectasis.
Implications for research
Our review highlights the need for additional long-term ran-
domised placebo-controlled trials to determine the effectiveness of
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dual antibiotics versus single antibiotics for treatment of adults and
children with bronchiectasis. The two included studies compared
oral plus inhaled dual therapy versus oral therapy alone, but no tri-
als have compared other combinations of modes of administration
(e.g. intravenous and inhaled; different antibiotics delivered via a
commonmode of administration, such as two inhaled antibiotics).
Some evidence from observational studies of dual antibiotic regi-
mens suggests that including nebulised antibiotics ismore effective
than providing intravenous regimens alone for eradicating Pseu-
domonas aeruginosa. (Orriols 1999), This and other comparisons
require formal testing in randomised controlled trials to establish
the relative benefits of different types of dual therapy. The overall
quality of evidence derived from the two included studies is very
poor, and we found no data on our primary outcomes of duration,
frequency, or time to next exacerbation, nor on our secondary
outcomes of microbiological infection measures, exercise capacity,
and quality of life. Furthermore neither of the included trials en-
rolled children or investigated long-term (more than four weeks)
use of dual antibiotic therapy. Future high-quality studies should
consider both short- and long-term antibiotic management for
adults and children including our prespecified review outcomes,
especially health-related quality of life, and should report data on
adults and children separately. We also consider it important to
assess the relative risks and benefits of continuous versus cyclical
antibiotic administration, but this question will be addressed in a
separate review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bilton 2006
Methods Aims: to test the effect of adding tobramycin inhaled solution to oral ciprofloxacin for
the treatment of acute exacerbations of non-cystic fibrosis bronchiectasis in patients with
P aeruginosa infection
Design: a double-blind, randomised, active comparator, parallel-design study
Total study duration: 42 days from randomisation, not including the 28-day pre-
screening run-in period. Elapsed time between pre-screening and randomisation differed
for each participant as participants were randomised during an exacerbation
Number of study centres and locations: multiple (17 centres): 5 in the United King-
dom, 12 in the United States
Study setting: home (participants received the first dose of study drug on day 1 in the
presence of study personnel but took subsequent doses at home)
Methods of recruitment: unclear
Study start and end dates: not reported
Withdrawals: 10 participants withdrew from the study (5 from inhaled tobramycin +
oral ciprofloxacin group, 5 from oral ciprofloxacin group). Seven withdrawals (2 from
inhaled tobramycin + oral ciprofloxacin group and 5 from oral ciprofloxacin group)
were due to adverse events. Among these, 3 participants (1 from inhaled tobramycin
+ oral ciprofloxacin group, and 2 from oral ciprofloxacin group) withdrew owing to
possibly drug-related adverse events, and 4 in the oral ciprofloxacin group withdrew
on day 21 or later owing to non-drug-related adverse events. Three participants in
the inhaled tobramycin + oral ciprofloxacin group withdrew from the study owing to
“unsatisfactory therapy responses” after receiving 8, 8, and 15 days of dosing, respectively.
One participant from the inhaled tobramycin + oral ciprofloxacin group who withdrew
at day 8 owing to “unsatisfactory therapeutic responses” also had an adverse event
Analysis by intent to treat: yes. It was reported that “safety and efficacy analysis was
performed on the study population, which included all randomised participants who
had received at least one dose of study medication.”
Participants 53 adults were randomised
Inclusion criteria:history of chronicP aeruginosa lung infection, confirmed by a sputum
culture that was positive for P aeruginosa both within 12 months before screening and
at the time of screening. In addition, P aeruginosa had to show ciprofloxacin sensitivity
(mic < 4) at the time of study enrolment. Participants who did not experience an acute
exacerbation within 2 months of the screening visit were rescreened for study eligibility
Exclusion criteria: cystic fibrosis, allergic bronchopulmonary aspergillosis, active tuber-
culosis, glucose-6-phosphate dehydrogenase deficiency, significant renal disease, change
in steroid therapy within 2 weeks of exacerbation
Mean age: inhaled tobramycin + oral ciprofloxacin: 61.4 years; placebo/ciprofloxacin:
63.7 years
Age range: 18 to 80 years
Gender: inhaled tobramycin + oral ciprofloxacin group: 20 women, 6 men; placebo/
ciprofloxacin group: 18 women, 9 men
Diagnostic criteria:men and women between 18 and 80 years of age with bronchiectasis
confirmed by central reading of an HRCT scan
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Bilton 2006 (Continued)
Severity of condition: not stated
Baseline lung function: placebo/ciprofloxacin group: FEV1 51.4% predicted, FVC 70.
4% predicted. Inhaled tobramycin + oral ciprofloxacin group: FEV1 53.2% predicted,
FVC 70% predicted
Smoking history: placebo/ciprofloxacin group: current smokers 0, former smokers 10.
Inhaled tobramycin + oral ciprofloxacin group: current smokers 1, former smokers 7
Baseline imbalances: No significant imbalances were identified. 13% of ciprofloxacin-
resistant participants were excluded from the study
Interventions Inhaled tobramycin + oral ciprofloxacin group (n = 26)
Ciprofloxacin
Dose: 750 mg
Delivery mode: oral
Frequency: twice daily
Duration: 14 days
Tobramycin inhaled solution
Dose: 300 mg per 5 mL
Delivery mode: aerosolised with the use of a jet nebuliser
Frequency: twice daily
Duration: 14 days
Ciprofloxacin + placebo group (n = 27)
Ciprofloxacin
Dose: 750 mg
Delivery mode: oral
Frequency: twice daily
Duration: 14 days
Placebo
Dose: 1.25 mg quinine sulphate per 5 mL
Delivery mode: aerosolised with the use of a jet nebuliser
Frequency: twice daily
Duration: 14 days
Adherence: Study personnel were present during administration of the first dose on day
1
Run-in phase: 28 days
Run-out phase: none
Participants were not allowed to use inhaled tobramycin within 28 days before screening
or between screening and exacerbation event. Maintenance therapy with antibiotics,
including aerosolised antibiotics other than inhaled tobramycin, was allowed up until the
time of exacerbation; no changes were permitted within 14 days before the exacerbation
and during the study period
Outcomes Participants kept a structured respiratory symptoms diary
Primary
Clinical efficacy: assessed on days 14, 21, and 42, and classified as follows
Day 14
• Resolved (all signs and symptoms returned to pre-exacerbation state)
• Improved (but condition had not fully resolved or there were residual symptoms)
• Not improved (no change or condition has worsened)
Day 21
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Bilton 2006 (Continued)
• Cured (resolution or improvement in symptoms of acute exacerbation)
• Failed (persistence or worsening of symptoms of exacerbation, hospitalisation, or
administration of additional antimicrobial therapy)
• Indeterminate (participants with missing data or without a clear cure or fail
response)
Day 42
• Cured
• Failed
• Indeterminate
• Relapsed (cured on day 21, but subsequently requiring treatment with additional
antibiotics)
Sputum microbiology was classified on day 21 as follows, based on sputum culture
findings
• Eradicated (no P aeruginosa infection/unable to produce sputum)
• Persistent (P aeruginosa infection and/or treated with additional antibiotics for
continued infection)
• Superinfected (new pathogen and new or worsening symptoms of infection)
• Indeterminate (did not fit in to any of the above categories)
Secondary
Pulmonary function tests: FEV1 (L) assessed on days 0, 7, and 14
Adverse event rate
Post hoc analysis: concordance of clinical and microbiological outcomes at day 21,
which included clinical efficacy (cured) and P aeruginosa eradication
Notes Power calculation: not reported
Trial registration: not reported
Conflicts of interest: not reported
Funders: not reported
Role of the sponsors: not reported
Ethical approval: achieved at each participating centre
Conclusions:
“The addition of an inhaled tobramycin solution to therapy with oral ciprofloxacin for
the treatment of acute exacerbations of bronchiectasis due to P aeruginosa improved
microbiological outcome and was concordant with clinical outcome; the inability to
demonstrate an additional clinical benefit may have been due to emergent wheeze re-
sulting from treatment”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (from correspondence): “randomi-
sation was computer generated with sites
telephoning the company’s central number
in order to allocate the specific numbered
vials”
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Bilton 2006 (Continued)
Allocation concealment (selection bias) Low risk Correspondence with the principal investi-
gator of the study confirmed that random
sequence was allocated centrally
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (from correspondence): “patients
and the research team were blinded as the
placebo was supplied by the company who
made TOBI (by then I think it was Novar-
tis) and the placebo contained something
to make it taste the same as TOBI”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (from correspondence): “assessment
of endpoints was also blind as none of the
patients filling in symptom questionnaires
and none of the lab staff working on the
microbiology knew which treatment a pa-
tient was on”
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 5participants in the inhaled tobramycin
+ oral ciprofloxacin group who withdrew
from the study, 2 withdrew owing to drug-
related adverse events and 3 because of an
“unsatisfactory therapeutic response” after
receiving at least 8 days of study drug. In
the oral ciprofloxacin group, only 1 par-
ticipant withdrew owing to drug-related
adverse events and the remaining 4 with-
drawals were attributed to non-drug-re-
lated adverse events
Comment: Reasons for missing outcome
datawere imbalanced between the 2 groups
and may have been related to the interven-
tion
Selective reporting (reporting bias) Unclear risk Insufficient information available to per-
mit a judgement of ’low risk’ or ’high risk.
’ Trial authors acknowledge that impor-
tant outcomes such as time-to-next-exacer-
bation and time-to-next- exacerbation-re-
quiring-hospitalisation were not assessed in
this study
Other bias Low risk The study appears to be free of other
sources of bias
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Hossain 2010
Methods Aims: to investigate the efficacy of adding nebulised gentamicin to systemic antibiotics
to improve clinical outcomes during an exacerbation of bronchiectasis. The clinical
outcome was categorised as follows: resolved, improved but not fully resolved, or not
improved
Design: randomised controlled trial
Total study duration: 21 days
Number of study centres and locations: single; Dhaka, Bangladesh
Study setting: National Institute of Diseases of the Chest
Methods of recruitment: unclear
Study start and end dates: not reported
Analysis by intent to treat: not stated
Withdrawals: 11 in total, 3 from the nebulised gentamicin + systemic antibiotic group
and 8 from the placebo + systemic antibiotic group. Withdrawals were due to failure to
attend follow-up clinic
Exact withdrawals are unclear owing to inconsistent reporting in the abstract: nebulised
gentamicin + systemic antibiotic group started with 35 participants, with 3 withdrawals
leaving 32, but the abstract states that 30 participants completed the study in the nebu-
lised gentamicin + systemic antibiotic group
Participants 65 adults were randomised
Settings: National Institute of Diseases of the Chest
Country: Bangladesh
Inclusion criteria: diagnosis of bronchiectasis deemed to be exacerbating and treated
with systemic antibiotics
Exclusion criteria: not reported
Methods of recruitment: not reported
Mean age: not reported
Age range: not reported
Gender: not reported
Diagnostic criteria: not reported
Severity of condition: not reported
Baseline lung function : not reported
Smoking history : not reported
Baseline imbalances: not reported
Interventions Nebulised gentamicin + systemic antibiotic group (n = 35)
Dose: not stated
Placebo + systemic antibiotic group (n = 30)
Dose: not stated
Adherence: not reported
Run-in phase: not reported
Run-out phase: not reported
Outcomes Primary: exacerbation status classified at days 3, 7, 14, and 21 as follows
• Resolved - resolution of S/S of acute exacerbation
• Improved - not fully resolved
• Not improved - if no change or deterioration in S/S
Secondary: not reported
Post hoc analysis: not reported
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Hossain 2010 (Continued)
Notes Power calculation: not reported
Trial registration: unclear
Conflicts of interest: not reported
Funders: not reported
Role of the sponsors: not reported
Ethical approval: not reported
Conclusions:
“(1) Addition of nebulized gentamicin to systemic antibiotic improves clinical efficacy
compared to only systemic antibiotic. (2) It can reduce hospital stay when used as
adjuvant with systemic antibiotic for the treatment of exacerbation of bronchiectasis”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details of the randomisation process were
not reported
Allocation concealment (selection bias) Unclear risk Details of the allocation process were not
reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study was not described as blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The assessment was not described as
blinded. The outcome assessment included
severity of exacerbation, but it is not clear
how this was assessed or by whom
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3 from intervention group and 8 from
placebo group did not attend follow-up vis-
its, but no further details are reported
Selective reporting (reporting bias) Unclear risk Only data reported in an abstract were
available
Other bias Unclear risk The abstract did not report baseline values,
so the potential for baseline imbalances was
unclear. Similarly, no data were provided
on route of administration of systemic an-
tibiotics nor on adherence
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HRCT: high-resolution computed tomography; MIC:
minimum inhibitory concentration; TOBI:Tobramycin
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Orriols 1999 Did not meet inclusion criteria for the intervention. Nebulised dual antibiotic vs symptomatic treatment (i.e.
comparison arm was not given a monotherapy antibiotic)
Orriols 2015 Did not meet inclusion criteria for the intervention. The study compared nebulised dual antibiotics with symp-
tomatic treatment (i.e. comparison arm was not given a monotherapy antibiotic)
Takamoto 1994 The intervention was not exclusively restricted to participants with bronchiectasis, and it is unclear whether
the study was randomised. We were unable to contact trial authors for clarification on study design or data on
participants with bronchiectasis alone
Vergnon 1985 The intervention was not exclusively restricted to participants with bronchiectasis, and we were unable to contact
trial authors for data on these participants alone
Watanabe 1990 The intervention was not exclusively restricted to participants with bronchiectasis, and it is unclear whether
the study was randomised. We were unable to contact trial authors for clarification on study design or data on
participants with bronchiectasis alone
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D A T A A N D A N A L Y S E S
Comparison 1. Oral + inhaled dual therapy versus oral monotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Successful treatment of
exacerbation: cured (day 21)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Successful treatment of
exacerbation: cured (day 42)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Pseudomonas eradication 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Serious adverse events 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Treatment failure (day 21) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Treatment relapse (day 42) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Treatment failure (day 42) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Microbiological response:
eradicated
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Microbiological response:
persistent
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Microbiological response:
superinfected
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
11 Adverse events (any) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
12 Adverse events: wheeze 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
13 Adverse events related to study
medications
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 1 Successful
treatment of exacerbation: cured (day 21).
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 1 Successful treatment of exacerbation: cured (day 21)
Study or subgroup Dual therapy Monothrapy Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 13/26 19/27 0.42 [ 0.14, 1.30 ]
0.01 0.1 1 10 100
Favours monotherapy Favours dual therapy
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Analysis 1.2. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 2 Successful
treatment of exacerbation: cured (day 42).
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 2 Successful treatment of exacerbation: cured (day 42)
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 9/26 12/27 0.66 [ 0.22, 2.01 ]
0.01 0.1 1 10 100
Favours monotherapy Favours dual therapy
Analysis 1.3. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 3 Pseudomonas
eradication.
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 3 Pseudomonas eradication
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 9/26 5/27 2.33 [ 0.66, 8.24 ]
0.01 0.1 1 10 100
Favours monotherapy Favours dual therapy
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Analysis 1.4. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 4 Serious
adverse events.
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 4 Serious adverse events
Study or subgroup Dual Mono Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 2/26 4/27 0.48 [ 0.08, 2.87 ]
0.01 0.1 1 10 100
Favours dual therapy Favours monotherapy
Analysis 1.5. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 5 Treatment
failure (day 21).
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 5 Treatment failure (day 21)
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 10/26 5/27 2.75 [ 0.79, 9.62 ]
0.01 0.1 1 10 100
Favours dual therapy Favours monotherapy
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Analysis 1.6. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 6 Treatment
relapse (day 42).
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 6 Treatment relapse (day 42)
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 3/26 5/27 0.57 [ 0.12, 2.69 ]
0.01 0.1 1 10 100
Favours dual therapy Favours monotherapy
Analysis 1.7. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 7 Treatment
failure (day 42).
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 7 Treatment failure (day 42)
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 10/26 5/27 2.75 [ 0.79, 9.62 ]
0.01 0.1 1 10 100
Favours dual therapy Favours monotherapy
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Analysis 1.8. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 8
Microbiological response: eradicated.
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 8 Microbiological response: eradicated
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 9/24 5/25 2.40 [ 0.67, 8.65 ]
0.01 0.1 1 10 100
Favours monotherapy Favours dual therapy
Analysis 1.9. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 9
Microbiological response: persistent.
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 9 Microbiological response: persistent
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 13/24 19/25 0.37 [ 0.11, 1.26 ]
0.01 0.1 1 10 100
Favours dual therapy Favours monotherapy
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Analysis 1.10. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 10
Microbiological response: superinfected.
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 10 Microbiological response: superinfected
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 1/24 0/25 3.26 [ 0.13, 83.90 ]
0.01 0.1 1 10 100
Favours dual therapy Favours monotherapy
Analysis 1.11. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 11 Adverse
events (any).
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 11 Adverse events (any)
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 22/26 26/27 0.21 [ 0.02, 2.03 ]
0.01 0.1 1 10 100
Favours dual therapy Favours monotherapy
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Analysis 1.12. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 12 Adverse
events: wheeze.
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 12 Adverse events: wheeze
Study or subgroup Dual therapy Monotherapy Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 13/26 4/27 5.75 [ 1.55, 21.33 ]
0.01 0.1 1 10 100
Favours dual therapy Favours monotherapy
Analysis 1.13. Comparison 1 Oral + inhaled dual therapy versus oral monotherapy, Outcome 13 Adverse
events related to study medications.
Review: Dual antibiotics for bronchiectasis
Comparison: 1 Oral + inhaled dual therapy versus oral monotherapy
Outcome: 13 Adverse events related to study medications
Study or subgroup Dual therapy Monotherapy Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2006 13/26 11/27 1.45 [ 0.49, 4.31 ]
0.01 0.1 1 10 100
Favours dual therapy Favours monotherapy
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
CENTRAL (the Cochrane Library) Monthly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
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Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and the RCT filter (Lefebvre 2011) were adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Anti-Bacterial Agents Explode 1
#6 antibiotic* or anti-biotic*
#7 anti-bacteri* or antibacteri*
#8 *cillin
#9 *mycin or micin*
#10 *oxacin
#11 *tetracycline
#12 macrolide*
#13 quinolone*
#14 trimethoprim
#15 ceph*
#16 sulpha*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
[In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectasis]
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C O N T R I B U T I O N S O F A U T H O R S
All review authors contributed to the background, discussion, and conclusions. Lambert Felix, Stephen Milan, and Sally Spencer
contributed to the methods and results sections.
Haley Harrison searched trial registries. Seamus Grundy and Lambert Felix contributed to screening of searches and identifying the
included studies. Ross Armstrong, Dave Lynes, and Lambert Felix extracted data and completed the risk of bias assessment. Dave Lynes
transferred data into Review Manager. Lambert Felix and Sally Spencer undertook data analyses.
D E C L A R A T I O N S O F I N T E R E S T
Sally Spencer, Dave Lynes, and Ross Armstrong are named co-investigators on a study funded by Edge Hill University to develop a
series of reviews on bronchiectasis; Lambert Felix is a part-time review author supported by this funding; Haley Harrison received
funding support through an NIHR internship. The remaining review authors did not receive funding for this systematic review.
S O U R C E S O F S U P P O R T
Internal sources
• Edge Hill University, UK.
Funded a part-time review author (LF) to support a series of reviews on bronchiectasis
External sources
• The review authors declare that no such funding was received for this systematic review, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have noted no differences between the review and the planned protocol, although we found insufficient evidence to conduct all
pre-planned analyses.
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